MindImmune Receives $5M Investment to Advance Neuroinflammation Therapeutics

Memory is a fragile thing. Billions of neurons firing in rhythm, protected by a brain that depends on the immune system behaving like a disciplined security team. When that discipline breaks, inflammation creeps in, synapses weaken, and diseases like Alzheimer’s start stealing moments people spent a lifetime building. MindImmune Therapeutics is working on the part of the story most people overlook: the immune system’s role in the chaos.

That mission just picked up serious momentum. MindImmune Therapeutics secured a $5M strategic investment from the Alzheimer’s Drug Discovery Foundation, an organization known for backing programs that move beyond theory and toward real clinical impact. When the Alzheimer’s Drug Discovery Foundation commits capital, it signals more than interest. It signals belief that the science deserves a serious run at the clinic.

At the center of the company’s approach is MITI 101, a monoclonal antibody designed to stop specific neuroinflammatory innate immune cells from leaving the bloodstream and entering the brain. Those cells, once inside, can trigger inflammatory cascades that damage synapses and blood vessels tied directly to cognition. MindImmune Therapeutics is not waiting until the damage is done. The strategy is to intercept the problem at the border before inflammation starts rewriting the brain’s circuitry.

The idea traces back to the company’s scientific roots. Co-founders Stevin Zorn, Frank Menniti, Robert Nelson, and Brian Campbell spent years inside the CNS drug discovery trenches at Pfizer and later at H. Lundbeck A/S, where they helped build one of the earliest pharmaceutical programs focused on neuroinflammation. Eventually the team partnered with the University of Rhode Island and turned that experience into a venture-backed company dedicated to immune-driven therapies for neurodegenerative disease.

CEO Isaac Stoner is now guiding MindImmune Therapeutics through the next stage of the journey. The Alzheimer’s Drug Discovery Foundation investment will fund critical translational studies, support preparation of an Investigational New Drug application, and help position MITI 101 for early clinical development in Alzheimer’s disease. It is the phase where a promising concept tightens its data package and prepares to walk into the clinic.

The broader lesson here sits at the intersection of persistence and pattern recognition. The MindImmune Therapeutics team did not arrive at this moment chasing headlines. They built a thesis around the immune system’s influence on brain health long before the space became fashionable. That discipline helped attract investors including Dolby Family Ventures, Pfizer Ventures, Gates Frontier, Slater Technology Fund, RightHill Ventures, and Foundation for a Better World, who backed the company’s $30M Series A financing.

Biotech rewards patience and precision. The immune system is one of the most powerful biological forces in the human body, capable of protecting or damaging depending on how it is guided. MindImmune Therapeutics is betting that controlling how immune cells interact with the brain could change the trajectory of Alzheimer’s disease. And with fresh support from the Alzheimer’s Drug Discovery Foundation, that bet just gained a little more oxygen with $5M behind the science.